全血中氯霉素的固相萃取方法

目的建立全血中氯霉素的固相萃取方法。方法在空白血中添加标准氯毒素,采用HLB、MCX固相柱萃取,HPLC法测定了线性范围、精密度、回收率。结果回收率分别为：HLB为69.1%,RSD为6.21%,MCX为70.1%,RSD为4.34%。标准工作曲线Y=18.1094X-0.4822,相关系数r=0.9999,线性范围1.0-20.0ug/L,最小检出量3ng。标准添加工作曲线Y=-2.1165X＋14.0459,相关系数r=0.9996,最小检出限0.5μg/mL（S/N=10∶1）。结论此二种萃取柱均可用于氯霉素的固相萃取。     

SPE-HPLC/MS/MS法检测人唾液中地西泮及其代谢物

目的采用固相萃取-高效液相色谱-串联质谱法(SPE-HPLC/MS/MS)检测人唾液中地西泮及其代谢物。方法采用固相萃取法(SPE)处理唾液,HPLC/MS/MS法检测,MRM记录方式,保留时间和定性离子对定性,内标法和标准曲线法定量。结果地西泮及其代谢物去甲地西泮、去甲羟基西泮、去甲羟基地西泮葡萄糖醛酸苷(OG)、羟基地西泮葡萄糖醛酸苷(TG)的检测限在0.01ng/m L~0.5ng/m L之间,线性范围0.1ng/m L或0.5ng/m L~100ng/m L,回收率为84.9%~106%。口服5mg地西泮后15d内唾液中可检出地西泮及去甲西泮,但检出时间有个体差异,但去甲羟基西泮、TG和OG则不能检出。结论 SPE-HPLC/MS/MS检测法可应用于人唾液中地西泮及其代谢物的检测。人口服常量地西泮后唾液中可检出地西泮和去甲西泮,且检测窗口期较宽,但存在个体差异。     

血液中乌头碱、次乌头碱、新乌头碱的LC/MS/MS分析

目的　建立血液中乌头碱、次乌头碱、新乌头碱的LC/MS/MS分析方法。方法　用 1%三氯乙酸 乙腈萃取血液样品 ,采用电喷雾离子源 ,正离子MRM扫描。结果　本方法线性相关系数r≥ 0 992 2。最低检测浓度(LOQ ,S/N =5 )分别为乌头碱 2 0ng/ml ,次乌头碱 0 5ng/ml ,新乌头碱 0 5ng/ml。空白血添加回收率 91 2 5 %～10 3 1%,变异系数 (CV ,n =6) <10 93 %。结论　LC/MS/MS法灵敏可靠 ,样品处理快速简便 ,适用于血液中乌头碱、次乌头碱、新乌头碱的检测。     

LC／MS／MS法测定生物组织中百草枯

目的建立LC／MS／MS检测生物体液中百草枯方法。方法弱阳离子交换固相萃取小柱提取剂，应用LC／MS／MS法对生物样品中百草枯进行定性定量分析。结果经该方法测得百草枯的最小检出限为10ng／ml血（S／N≥3），线性范围为0．02～20μg／ml。结论该方法快速、灵敏、准确，适用于生物检材中百草枯的分析。     

SPE-LC/MS/MS法检验血尿中的茚地普隆

建立了新型非苯二氮唑类镇静催眠药茚地普隆的LC/MS/MS定性定量检测及血、尿等生物检材的自动固相萃取提取方法.实验结果表明,本方法准确、快速、高效,可以满足新型镇静药物茚地普隆的日常检验工作需要.     

固相萃取/气相色谱法检测全血中的扎来普隆

目的建立全血中扎来普隆的固相萃取/气相色谱检测方法。方法采用Oasis HLB固相萃取柱,5%甲醇水淋洗,二氯甲烷洗脱,GC/NPD定量检验,GC/MS定性检验,并对检测条件进行考察。结果扎来普隆与血中杂质分离良好,平均萃取回收率达89%以上,最低检出限20ng/mL,50～2000ng/mL内线性良好,相关系数R2=0.9945,日内RSD为3.1%～4.2%,日间RSD 5.8%～6.7%。结论该方法操作简便快速,提取回收率高,重现性好,提取物杂质少,可用于实际案件的检验。     

血中毒鼠强的固相萃取和GC-NPD法测定

目的 研究人全血中毒鼠强的固相革取(SPE)。方法 用Bond Elute C18固相萃取柱萃取,GC-NPD检测,以甲基对硫磷为色谱内标(CS)。结果 全血中加标0.5μg/ml,毒鼠强回收率为92.5％,变异系数2.3％(CV,n=4)。在0.5～10μg/ml的浓度范围内,线性相关系数为0.9994。检出限(S/N=3)和定量限(S/N=10)分别为6ng/ml和20ng/ml。同一根萃取柱连续使用6次未见性能明显下降(CV=3.6%)。结论 本文方法适用于毒鼠强中毒的全血测定。     

生物样品中去痛片4种成分及其8种代谢物的GC-MS/MS法检测

目的建立固相支撑液液萃取(supported liquid-liquid extraction,SLE),GC-MS/MS法同时测定生物样品中去痛片4种成分及其8种代谢物的方法,为去痛片相关案件的法医学鉴定提供依据。方法采用SLE萃取,GC-MS/MS检测,MRM记录方式,利用保留时间和离子对比例定性,内标法和工作曲线法定量,建立血液和组织中去痛片及其代谢物的GC-MS/MS检测方法。结果经SLE萃取,GC-MS/MS法同时检测大鼠血和组织中去痛片及其代谢物,萃取率为37.57%~95.87%,检测线性范围为0.12μg/m L~16.00μg/m L,相关系数(r)为0.989 6~0.999 7,LOD为0.23ng/m L~14.48ng/m L,检测准确度为79.63%~122.90%,日内和日间精密度分别为0.99%~7.43%和2.19%~10.6%。结论 SLE萃取、GC-MS/MS法可检测生物样品中去痛片成分及其代谢物,具有快速、简便、准确度和精密度高的特点,可应用于去痛片相关案件的法医学鉴定。     

HPLC-MS/MS方法检验血液中可待因

目的 采用HPLC-MS/MS方法对血液中可待因进行定性、定量检验.方法 以Clean Screen DAU混合阳离子交换固相萃取柱提取血样,应用HPLC色谱法分离,MS/MS检测分析.结果 该方法回收率高于70％,线性范围0.01～2 μg/mL,检测限0.1ng(S/N≥3).结论 本文方法快速、灵敏、准确,可用于血液中可待因的定性、定量分析检验.     

氯硝安定在生物体内的代谢

目的推测氯硝安定在生物体内的主要代谢方式,检测其代谢产物。方法取5只Wistar大鼠,连续3d给每只大鼠灌胃氯硝安定（剂量分别为1、2、2mg）,收集灌胃后24h内尿液;给3只大鼠各灌胃2mg氯硝安定,2h后处死,取血液和肝组织等检材;收集3名口服5mg氯硝安定的志愿者24h内尿液。分别对不同检材进行处理后,气相色谱/质谱联用（GC/MS）检测。结果在大鼠阳性尿液和志愿者阳性尿液中,均检出7-乙酰氨基氯硝安定和7-氨基氯硝基安定;在大鼠血液中,主要检出氯硝安定和7-氨基氯硝基安定;在大鼠肝组织中,主要检出7-乙酰氨基氯硝安定,还有少量7-氨基氯硝安定和氯硝安定。结论氯硝安定进入生物体后,其7位硝基被还原为氨基,氨基接着被乙酰化,形成7-氨基氯硝基安定和7-乙酰氨基氯硝安定代谢物,其中7-乙酰氨基氯硝安定为主要代谢物。     

HPLC-MS/MS法快速检测人体血液中的夹竹桃毒素

目的采用高效液相色谱-串联质谱法(HPLC-MS/MS)检测人体血液中夹竹桃苷、夹竹桃苷乙。方法采用乙腈沉淀蛋白法处理血液,HPLC-MS/MS法检测,采用MRM记录方式,保留时间和定性离子对定性,标准曲线法定量。结果夹竹桃苷、夹竹桃苷乙的检测限均在0.5ng/m L,线性范围在1ng/m L~1mg/m L,回收率为75.2%~95.7%。结论本方法操作简便,灵敏度高,可应用于中毒案件中人体血液中两种夹竹桃毒素(夹竹桃苷和夹竹桃苷乙)的快速检测。     

HPLC-MS／MS同时检测全血中佐匹克隆、唑吡坦和扎来普隆

目的建立全血中佐匹克隆、唑吡坦和扎来普隆的液相色谱一四级杆飞行时间串联质谱联用同时检测方法。方法采用液液萃取进行提取,提取物以ZorbaxEclipsePlusC18（2．1×50mm,1．8fire）色谱柱分离,以10mmol／L甲酸铵（含0．1％甲酸）一乙腈为流动相梯度洗脱,流速为0．2mL／min,四级杆一飞行时间串联质谱检测。结果全血中佐匹克隆和扎来普隆的线性范围为10ng／mL-500ng／mL,检出限为3ng／mL唑吡坦的线性范围为3ng／mL-300ng／mL,检出限为lng／mL。结论本方法准确、快速、灵敏,可用于全血中佐匹克隆、唑吡坦和扎来普隆的同时定性、定量检测。     

人血浆中氟康唑的高效液相色谱分析

目的建立血浆中氟康唑的高效液相色谱分析方法。方法以正常空白人血浆添加标准氟康唑及内标物对样品的前处理方法、仪器测试条件、定性定量分析方法进行考察和优化。对10名健康受试者单剂量口服氟康唑的药代谢动力学进行测定。结果血浆中氟康唑在0.25~10.0μg/ml范围内线性关系良好(r=0.9986);定量检测的浓度下限是0.25μg/ml;检出限为0.1μg/ml;分析方法的精密度日内RSD≤2.9%、日间RSD≤8.3%(n=5);氟康唑在血液中的相对回收率在97.0±2.8%和108.4±2.4%之间;结论所建高效液相色谱分析方法准确、便捷,适应于法医学鉴定、临床血药浓度监测和药代动力学研究。     

Evaluation of the One-Step ELISA kit for the detection of buprenorphine in urine, blood, and hair specimens

A solid-phase enzyme immunoassay involving microtiter plates was recently proposed by International Diagnostic Systems corporation (IDS) to screen for buprenorphine in human serum. The performance of the kit led us to investigate its applicability in other biological matrices such as urine or blood, and also hair specimens. Low concentrations of buprenorphine were detected with the ELISA test and confirmed by HPLC/MS (buprenorphine concentrations measured by HPLC/MS: 0.3 ng/mL in urine, 0.2 ng/mL in blood, and 40 pg/mg in hair). The intra-assay precision values were 8.7% at 1 ng/mL of urine (n = 8), 11.5% at 2 ng/mL in serum (n = 8), and 11.5% at 250 pg/mg of hair (n = 8), respectively. The immunoassay had no cross-reactivity with dihydrocodeine, ethylmorphine, 6-monoacetylmorphine, pholcodine, propoxyphene, dextromoramide, dextrometorphan at 1 and 10 mg/L, or codeine, morphine, methadone, and its metabolite EDDP. A 1% cross-reactivity was measured for a norbuprenorphine concentration of 50 ng/mL. Finally, the immunoassay was validated by comparing authentic specimens results with those of a validated HPLC/MS method. From the 136 urine samples tested, 93 were positive (68.4%) after the ELISA screening test (cutoff: 0.5 ng/mL) and confirmed by HPLC/MS (buprenorphine concentrations: 0.3-2036 ng/mL). From the 108 blood or serum samples screened, 27 were positive (25%) after the ELISA test with a cutoff value of 0.5 ng/mL (buprenorphine concentrations: 0.2-13.3 ng/mL). Eighteen hair specimens were positive (72%) after the screening (cutoff: 10 pg/mg) and confirmed by LC/MS (buprenorphine concentrations: 40-360 pg/mg). The ELISA method produced false positive results in less than 21% of the cases, but no false negative results were observed with the immunological test. Four potential adulterants (hypochloride 50 mL/L, sodium nitrite 50 g/L, liquid soap 50 mL/L, and sodium chloride 50 g/L) that were added to 10 positive urine specimens (buprenorphine concentrations in the range 5.3-15.6 ng/mL), did not cause a false negative response by the immunoassay.     

Deaths involving buprenorphine: a compendium of French cases

Buprenorphine at high dosage became available in France in 1996, as a substitution treatment for heroin addicts. Since this date, numerous deaths were attributed to this drug. This paper reports two original series of 39 and 78 fatalities involving buprenorphine observed at the Institute of Legal Medicine of Strasbourg and at 13 other French forensic centers, respectively. The files were recorded from January 1996-May 2000. The first 20 fatalities that were previously published were excluded from this epidemiological study. From these 117 subjects, 96 were male (82%). Buprenorphine and its primary metabolite norbuprenophine were assayed in post-mortem blood by HPLC/MS (n=11 labs) or by GC/MS (n=3 labs). Blood levels for buprenorphine ranged from 0.5 to 51.0ng/ml (mean 10.2ng/ml) and 0.1 to 76ng/ml (mean 12.6ng/ml) in Strasbourg and the other centers, respectively. Blood levels for norbuprenorphine ranged from 0.2 to 47.1ng/ml (mean 8.2ng/ml) and <0.1 to 65ng/ml (mean 10.6ng/ml) in Strasbourg and the other centers, respectively. The mean values appear to be within the therapeutic range. Buprenorphine was identified in 24 of the 26 hair samples assayed in Strasbourg, at concentrations ranging from 10 to 1080pg/mg. Intravenous injection of crushed tablets, a concomitant intake of psychotropics (especially benzodiazepines and neuroleptics) and the high dosage of the buprenorphine formulation available in France appear as the major risk factors for such fatalities. In addition, two suicide-related deaths were also observed, with blood buprenorphine concentrations at 144 and 3276ng/ml.     

HS/GC/ECD分析生物检材样品中的氰化物

目的 建立生物样品中氰化物的衍生化定性定量分析方法。方法 用氯胺T衍生化,HS/GC/ECD分析衍生物CICN。结果 在1ml血中,添加0.2μg氰化钾,回收率为84.6％,RSD为6.39％;在1g肝中添加0.5μg氰化钾,回收率为67.3％,RSD为5.05％;血中检出限为5ng/ml。结论 所建方法能定性定量分析生物样品中的氰化物。     

人血、尿中碘解磷定的高效液相色谱分析

目的建立人血、尿中碘解磷定的高效液相色谱分析方法,用于法医学鉴定和指导临床合理用药。方法以空白人血浆和尿液分别添加标准碘解磷定对样品的前处理方法、仪器测试条件、定性、定量分析方法进行考察和优化。对疑似有机磷中毒抢救或死亡者血、尿中的碘解磷定浓度进行测定。结果血、尿中碘解磷定浓度的线性范围是0.5~8.0μg/m l;定量检测的浓度限为0.5μg/m l;日内、日间精密度RSD≤5.3%(n=5);回收率:血≥(96.7±2.9)%;尿≥(93.7±3.8)%。结论所建分析方法快速、准确,适应于法医学鉴定和临床救治中碘解磷定血、尿浓度监测等相关研究。